Prostate cancer screening

Prostate cancer screening refers to the process of testing men who have no symptoms of the disease for the presence of prostate cancer, typically through the use of digital rectal exams and prostate-specific antigen (PSA) blood tests. The goal of prostate cancer screening is to detect the disease early, when it is most treatable, and to develop effective screening tests for this purpose.From: Design of Biomedical Devices and Systems [2018], Handbook of 3D Machine Vision [2019]

Diagnosing Prostate Cancer Based on Deep Learning with a Stacked Nonnegativity Constraint Autoencoder

View Chapter

Purchase Book

Published in Ayman El-Baz, Gyan Pareek, Jasjit S. Suri, Prostate Cancer Imaging, 2018

Islam Reda, Ahmed Shalaby, Mohammed Elmogy, Ahmed Aboulfotouh, Mohamed Abou El-Ghar, Adel Elmagharaby, Ayman El-Baz

Some of the major drawbacks with current prostate cancer screening are over diagnosis and overtreatment [20]. For instance, in an investigation that extended for 11 years of follow-up to determine the role of PSA and TRUS-guided biopsy in decreasing the mortality rate caused by prostate cancer, Schr¨oder et al. [21] found that to obviate one death from prostate cancer, more than 1000 men would need to be examined and 37 would need to be treated. These problems of overdiagnosis and overtreatment motivated research toward developing techniques to visualize such structures and their associated abnormalities.

Impact statement: Analyzing overdiagnosis risk in cancer screening: A case of screening mammography for breast cancer

View Article

Journal Information

Published in IISE Transactions on Healthcare Systems Engineering, 2018

Donna L. Williams

Screening has been one of the cornerstones for decreasing cancer mortality for decades, particularly for breast, cervical, and colorectal cancers. The Pap test became standard care in the 1970 s and has resulted in a plummet in cervical cancer cases and deaths. However, with population-based screening comes the risk of detecting and subsequently treating what would otherwise be clinically insignificant disease. This risk has been clearly seen with prostate cancer screening, where overtreatment of indolent disease can leave many men impotent, incontinent, depressed, and/or anxious (Sanhu and Andriole, 2012).

Prostate cancer screening

Explore chapters and articles related to this topic

Diagnosing Prostate Cancer Based on Deep Learning with a Stacked Nonnegativity Constraint Autoencoder

Impact statement: Analyzing overdiagnosis risk in cancer screening: A case of screening mammography for breast cancer